Although our study was not designed to statistically evaluate the effect of osimertinib across the spectrum of EGFR altered glioblastoma, these data showed that osimertinib failed to robustly inhibit 18F-FDG uptake in this cohort of EGFR-altered GBM patients per the PERCIST criteria. The gene discussed is EGFR; the disease is glioblastoma.